Background—Despite well-publicized guidelines on the appropriate management of cardiovascular disease and type 2 diabetes, the implementation of risk-reducing practices remains poor. This report describes the results of a randomized, controlled clinical trial evaluating the effectiveness of a comprehensive program of cardiovascular disease risk reduction delivered by nurse practitioner/community health worker (NP/CHW) teams versus enhanced usual care (EUC) to improve lipids, blood pressure, glycated hemoglobin (HbA1c), and patient perceptions of the quality of their chronic illness care in patients in urban community health centers.

Methods and Results—A total of 525 patients with documented cardiovascular disease, type 2 diabetes, hypercholesterolemia, or hypertension and levels of LDL cholesterol, blood pressure, or HbA1c that exceeded goals established by national guidelines were randomly assigned to NP/CHW (n = 261) or EUC (n = 264) groups. The NP/CHW intervention included aggressive pharmacological management and tailored educational and behavioral counseling for lifestyle modification and problem solving to address barriers to adherence and control. Compared with EUC, patients in the NP/CHW group had significantly greater 12-month improvement in total cholesterol (difference, 19.7 mg/dL), LDL cholesterol (difference, 15.9 mg/dL), triglycerides (difference, 16.3 mg/dL), systolic blood pressure (difference, 6.2 mm Hg), diastolic blood pressure (difference, 3.1 mm Hg), HbA1c (difference, 0.5%), and perceptions of the quality of their chronic illness care (difference, 1.2 points).

Conclusions—An intervention delivered by an NP/CHW team using individualized treatment regimens based on treat-to-target algorithms can be an effective approach to improve risk factor status and perceptions of chronic illness care in high-risk patients.

Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00241904.

Key Words: risk factors ■ secondary prevention ■ primary prevention ■ cardiovascular nursing ■ Type 2 diabetes ■ behavioral/psychosocial-treatment ■ compliance/adherence

A pproximately 831,000 Americans die annually of cardiovascular disease (CVD), with lower income, prior coronary heart disease (CHD), and diabetes populations differentially represented in these deaths.1 Despite well-publicized guidelines on the appropriate management of cardiovascular disease (CVD) and type 2 diabetes, implementation of risk-reducing practices remains poor. Several different models of chronic disease case management have emerged to respond to growing concerns about the quality and increasing costs of health care; however, evaluation of their impact on patient outcomes or cost is limited.

Received April 15, 2011; accepted August 22, 2011.

The online-only Data Supplement is available at http://circoutcomes.ahajournals.org lookup/suppl/doi:10.1161/CIRCOUTCOMES.111.961573/-/DC1.

Correspondence to Jerilyn K. Allen, RN, ScD, FAAN, Johns Hopkins University School of Nursing, 525 N Wolfe St, Baltimore, MD 21205. E-mail jallen@son.jhmi.edu

© 2011 American Heart Association, Inc.

Circ Cardiovasc Qual Outcomes is available at http://circoutcomes.ahajournals.org DOI: 10.1161/CIRCOUTCOMES.111.961573
Case management by a specially trained nurse-led team, including community health workers, has been shown to be among the most efficacious strategies to improve management of CVD risk factors in many studies. Several studies have shown that nurse management clinics are at least as beneficial in achieving goals as are other clinics managed by physicians, and in many cases actually result in marked improvement in the outcomes including patient satisfaction and utilization of health care services, compared with usual care. For example, trained nurses providing care have demonstrated successful strategies for improving lipid levels in patients with elevated low-density lipoprotein cholesterol (LDL-C) and blood pressure (BP). In the nurse management models, factors such as patient education and counseling and regular telephone follow-up by a nurse showed marked sustained improvement in medication adherence and goal achievement. Nurse case managers have been shown to improve adherence to guidelines in part by serving as a bridge to physician care and by adhering more strictly to management algorithms, including counseling features that are not within the time frame of a busy physician in practice. Several studies suggest that a nurse-led team management program is the most effective strategy to date for reducing LDL-C.

Nurses managing patients with diabetes also have a more favorable impact on chronic disease parameters, including adherence to recommendations for diet and for renal testing. Nurse case management improves control of diabetes in clinical settings, with significant reductions in fasting blood glucose, body weight, glycated hemoglobin, and LDL-C. Telephone management of diabetic patients by a nurse has been shown to markedly improve CVD risk factors, including lipids. Diabetic patients were more likely to be appropriately treated with a lipid lowering therapy when managed by the nurse over the phone than patients managed solely with usual care.

In low-income and minority populations, community health workers (CHWs) or lay health advisors have often participated in team-based care for the management of CVD risk factors, particularly hypertension and diabetes. Although there are too few randomized, clinical trials of the role of these individuals, there is sufficient collective experience to suggest that this role can be an important one in improving adherence in high-risk subsets of the population. Community health centers that are part of the federally qualified health center–community practice partnership to enhance the applicability and sustainability of the intervention.

WHAT THE STUDY ADDS
- An intervention delivered by a nurse practitioner/community health worker team using individualized treatment regimens based on treat-to-target algorithms improved cardiovascular disease risk factor status and perceptions of chronic illness care.
- The results of this trial support nurse-led patient-centered medical homes to improve the quality of cardiovascular disease care in high risk underserved populations.

Methods

Study Design
The complete methods of the Community Outreach and Cardiovascular Health (COACH) study have been detailed elsewhere. Briefly, we used community-based participatory research (CBPR) as a theoretical framework for this study. CBPR is a methodology that promotes active community involvement in the processes that shape research and intervention strategies, as well as the conduct of research studies. This research used a Community-Provider Advisory Committee to guide all aspects of the study.

COACH was a randomized, controlled trial in which 525 patients were randomly assigned to 1 of 2 groups: comprehensive intensive management of CVD risk factors by a NP/CHW team or an EUC control group. Individuals in the control group received usual care from their primary provider, which was enhanced by feedback regarding CVD risk factors provided to the patient and their provider. Those in the intensive intervention group received EUC plus management by the NP/CHW team. The program included aggressive pharmacological management, tailored educational and behavioral counseling for lifestyle modification, identification of barriers to adherence and control, phone follow-ups between visits and preappointment reminders.

Participants
Patients were recruited between July 2006 and July 2009 from 2 community health centers that are part of the federally qualified...
community health center entitled Baltimore Medical Systems Incorporated. The focus of these clinics is on primary care in communities designated as medically underserved areas. Patients identified from clinic-based computerized ICD 9 codes were eligible if they were African American or Caucasian and had diagnosed CVD defined as a prior MI, revascularization procedure for coronary disease, ischemic heart disease, stroke, peripheral vascular disease, or hypercholesterolemia, hypertension, or had diagnosed type 2 diabetes receiving any therapy. They had to be ≥21 years of age and able to speak and understand English. Patients were enrolled in the trial if they had at least 1 of the following criteria within the past 6 months at the time of the medical record reviews: (1) a LDL-C ≥100 mg/dL or LDL-C ≥130 mg/dL if no diagnosed CVD or diabetes, (2) BP >140/90 mm Hg or ≥130/80 mm Hg if diabetic or renal insufficiency, or (3) if diabetic, a HbA1c ≥7.0% or glucose ≥125 mg. Patients were excluded if they had a serious life-threatening noncardiac comorbidity with a life expectancy of less than 5 years (AIDS or cancer, for example), had a serious physician-recorded psychiatric morbidity that would preclude participating in their own care, or were sufficiently neurologically impaired to preclude participation in their own care.

Of the 3899 screened for eligibility, 525 were enrolled in the trial (Figure). The participants were randomly assigned, stratified by race and sex, to receive the NP/CHW intervention or EUC. All participants provided written informed consent. The protocol was approved by the Johns Hopkins University Institutional Review Board.

### Intervention

The NP/CHW intervention focused on behavioral interventions to effect therapeutic lifestyle changes (TLC) and adherence to medications and appointments as well as the prescription and titration of medications. Patients were followed for 1 year. The NP and CHW worked as a team. The NP functioned as the case coordinator for each study participant. She oversaw the initial assessment and tailored the intervention plan, conducted the intervention, including lifestyle modification, counseling, and medication titration and prescription, and consulted with the physician and supervised the CHW. Specific algorithms for drug treatment of hyperlipidemia, hypertension, hyperglycemia, as well as for angiotensin-converting enzyme and β-blocker therapy, were developed for this study based on current guidelines and standards of care. (Algorithms can be found in the online-only Data Supplement Appendix.)

In addition to meeting with the NP, patients and their support person met with the CHW, who spent additional time problem-solving anticipated barriers to treatment adherence, including issues important to the patient’s life which might not be directly related to cardiovascular health. The CHW also reinforced instructions by the NP related to integration of lifestyle modifications and medication therapies and assisted patients in designing a set of reminders, prompts, logs, pill organizers, alarm clocks, or whatever the individual believed would work for them to assist in following complex regimens. The intensity of the NP/CHW intervention was greater among those who had not yet achieved goals. Follow-up algorithms guided the frequency and type of follow-up. Those patients not making progress toward their goal levels received more frequent telephone follow-up from the CHW.

A low-literacy Wellness Guide was developed specifically for the study as a behavioral tool for the NP, CHW, and patient team to promote TLC. The patient received the guide at the first encounter, took it home as a tool for making changes, and was asked to bring it to each visit. The Wellness Guide had sections focusing on the patient’s laboratory results and therapeutic goals for weight, BP, lipids, and HbA1c (for patients with diabetes); medication reconciliation and customized tips for taking medicine; healthy eating, including strategies for portion control; increasing physical activity and a customized walking program; smoking cessation; and a place to record questions for future visits. Each section had a place for recording the patient’s goals, potential barriers, strategies to deal with difficult situations, and identification of ways to reward oneself, and identification of support people to help facilitate meeting goals. This section was completed during the counseling sessions with the NP and CHW.

The lifestyle behaviors of a healthy low-fat, low-sodium diet, regular moderate-intensity physical activity, and smoking cessation were the focus of TLC counseling interventions. The nurse initiated recommendations for healthy low-fat, low-sodium eating recommended in the TLC diet, adapted for diabetics according to standards of the American Diabetes Association.29 The importance of dietary adherence was emphasized as an adjunct to pharmacotherapy. Recognition of food preferences were important along with how to choose low-fat, low-sodium foods, modify recipes, self-monitor fat and sodium intakes, and develop individualized low-fat, low-sodium eating plans. Some areas of focus included reducing portion size, reducing fast food intake, and avoiding processed foods high in sodium and carbohydrates. Progress review of dietary patterns, strategies for dietary change, and guides for managing difficult situations were addressed with patients by the CHW.

Patients were instructed to participate in a moderate-intensity home-based exercise program. The patient selected the mode of moderate-intensity physical activity and set realistic goals. Telephone contact was initiated by the CHW 2 weeks after inception of the program and once a month until the sixth month to monitor progress, answer questions, and provide individualized feedback and positive reinforcement.

The intervention teams included NPs who were certified adult nurse practitioners with experience in the delivery of primary care and CHWs with experience working with underserved minority populations. The NPs completed additional continuing education in the management of hypertension, hypercholesterolemia, and diabetes, and the CHWs were trained in the disease pathophysiology of CHD and diabetes and therapeutic lifestyle management approaches of nutrition and physical activity. Both NPs and CHWs were trained in motivational interviewing behavior change techniques.

Documenting the team’s adherence to protocols was important to ensure intervention fidelity. Encounter forms for the NP and the CHW tracked the number, length, and content of the encounters (such as counseling on diet, exercise, medications, smoking cessation, and adherence) to determine the delivered dose of the intervention. In addition, there was a COACH Program Intervention Quality Assurance (QA) Plan to ensure adherence to study intervention protocols and treatment algorithms to promote intervention integrity throughout the study. QA assessments were conducted on a quarterly basis. The QA assessment included analysis of audiotape-recorded intervention sessions and intervention documentation in medical records. QA assessments were independently conducted by 2 COACH study investigators. The 2 independent reviewers discussed assessments and provided feedback to interventionists to provide positive reinforcement and/or a plan for additional training in a timely basis.
Patients and their providers in the EUC group received the results of baseline lipids, BP, and HbA1c along with the recommended goal levels and a pamphlet on controlling risk factors published by the American Heart Association. In addition, providers received copies of the American Heart Association/American College of Cardiology Guidelines for Secondary Prevention.30

Outcome Measures
The primary outcomes were changes from baseline to one year in lipids, BP, HbA1c, and patients’ perceptions of the quality of their chronic illness care. The primary outcomes also were operationalized as meeting the goals for secondary prevention or experiencing a clinically significant change as follows: HbA1c <7% or clinically significant decrease of ≥0.5%; systolic BP <140 mm Hg or <130 mm Hg if patient had diabetes or kidney disease or clinically significant decrease of ≥10 mm Hg; and LDL-C <100 mg/dL or <130 if no CVD or diabetes or a clinically significant decrease of ≥20%. The chemistry laboratory at Johns Hopkins performed all biochemical measures. Total cholesterol, triglycerides, and high-density lipoprotein cholesterol (HDL-C) were measured directly after a 12-hour fast. LDL-C was estimated using the Friedewald equation.31 In the event of triglyceride levels >400 mg/dL, direct measurement of LDL-C through ultracentrifugation methods was performed. In participants with diabetes, HbA1c was measured using high-pressure liquid chromatography. BP was measured using the Omron Digital Blood Pressure Monitor HEM-907XL automatic BP device according to JNC VII guidelines, after 5 minutes of quiet rest, in the right arm with the person seated in a chair with arm supported at heart level. The average of 3 BPs was recorded.

The patient’s ratings of care received from their health care team was measured by the Patient Assessment of Chronic Illness Care (PACIC) Survey, a 20-item patient report instrument that assesses patient’s perceptions of the receipt of clinical services and actions consistent with quality care defined by the Chronic Care Model.32 The 5 subscales are Patient Activation; Delivery System/Decision Support; Goal Setting; Problem-solving/Contextual Counseling; and Follow-up/Coordination.

Secondary outcomes included the lifestyle behaviors of dietary intake measured by the Habits and History Food Frequency Questionnaire, Block 2005.1,33,34 and physical activity was evaluated with the Stanford 7-Day Physical Activity Recall.35,36 Quality of life was measured by the 5-item EuroQol questionnaire,37 and resource utilization and patients’ health care utilization data were collected to conduct a cost effectiveness analysis, which will be reported separately.

Statistical Analysis
The sample size for this study was determined considering the effect sizes observed in the investigators’ preliminary work. Based on the calculations, a minimum of 450 participants (225 per group) were needed to detect clinically significant differences in changes in the primary outcomes of BP, LDL-C, and HbA1c at 1 year to ensure 80% power at a 0.05 significance level. This sample size accounted for an expected 25% attrition at the 1-year follow-up, yielding 180 participants per intervention. The data analysis for this report was generated using SAS version 9.2 for Windows. Statistical tests were used to study differences in baseline demographic, clinical, and risk factor characteristics, with a t test used for continuous variables and a χ² test for categorical variables. Similar statistical tests were used to compare baseline characteristics for subjects completing the study to those lost to follow-up for any reason.

The primary outcomes are changes from baseline to 1 year in lipids, BP, HgA1c, and the patient’s perception of chronic illness care. Analysis followed the intention-to-treat model including all randomly assigned participants in the analyses according to their original assignment. Participants who withdrew or did not complete the 1-year assessment were included in the analysis. Missing data were imputed with multiple imputation. Multiple imputation is an advanced statistical method for handling missing data.38 This computationally intensive approach uses multiple linear regression to predict missing values with observed data. The procedure is repeated with 5 iterations. Repeatedly imputing missing values allows for quantifying the uncertainty resulting from sampling error.

Generalized linear mixed models, using a random patient-level intercept model, were used to build multilevel models comparing the effectiveness of the NP/CHW intervention with EUC on each outcome, controlling for the covariates of age, sex, race, body mass index, and insurance status, which were determined by univariate analyses to be predictive of outcomes. Mixed models are the optimal statistical method to use with preintervention and postintervention repeated-measures data, as this modeling approach accounts for the correlated data structure.

### Table 1. Baseline Sample Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Intervention (n = 261)</th>
<th>Usual Care (n = 264)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y, mean (SD)</td>
<td>54.3 (12.0)</td>
<td>54.7 (11.5)</td>
<td>0.692</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>187 (71.7)</td>
<td>187 (70.8)</td>
<td>0.837</td>
</tr>
<tr>
<td>Marital status, n (%)</td>
<td>61 (23.4)</td>
<td>69 (26.1)</td>
<td>0.591</td>
</tr>
<tr>
<td>Single</td>
<td></td>
<td></td>
<td>0.946</td>
</tr>
<tr>
<td>Married</td>
<td>86 (33.0)</td>
<td>80 (30.3)</td>
<td>0.132</td>
</tr>
<tr>
<td>Widowed</td>
<td>19 (7.3)</td>
<td>28 (10.6)</td>
<td>0.318</td>
</tr>
<tr>
<td>Divorced</td>
<td>39 (14.9)</td>
<td>37 (14.0)</td>
<td>0.920</td>
</tr>
<tr>
<td>Race, n (%)</td>
<td></td>
<td></td>
<td>0.003</td>
</tr>
<tr>
<td>Black</td>
<td>270 (97.9)</td>
<td>210 (79.6)</td>
<td>0.051</td>
</tr>
<tr>
<td>Job status, n (%)</td>
<td>110 (42.2)</td>
<td>160 (61.2)</td>
<td>0.043</td>
</tr>
<tr>
<td>Education, n (%)</td>
<td>76 (29.1)</td>
<td>94 (35.6)</td>
<td>0.132</td>
</tr>
<tr>
<td>Type of insurance, n (%)</td>
<td>118 (45.2)</td>
<td>92 (34.9)</td>
<td>0.223</td>
</tr>
<tr>
<td>Annual income, n (%)</td>
<td>67 (25.7)</td>
<td>78 (29.6)</td>
<td>0.920</td>
</tr>
<tr>
<td>Comorbidity score, mean (SD)</td>
<td>1.6 (1.3)</td>
<td>1.8 (1.4)</td>
<td>0.132</td>
</tr>
<tr>
<td>LDL-C, mean (SD)</td>
<td>121.6 (40.0)</td>
<td>116.3 (40.5)</td>
<td>0.193</td>
</tr>
<tr>
<td>HDL-C, mean (SD)</td>
<td>50.8 (14.7)</td>
<td>50.9 (13.6)</td>
<td>0.883</td>
</tr>
<tr>
<td>Systolic blood pressure, mean (SD)</td>
<td>139.7 (23.8)</td>
<td>138.7 (19.9)</td>
<td>0.087</td>
</tr>
<tr>
<td>Total cholesterol, mean (SD)</td>
<td>199.7 (46.0)</td>
<td>191.3 (45.0)</td>
<td>0.036</td>
</tr>
<tr>
<td>LDL-C, mean (SD)</td>
<td>121.6 (40.0)</td>
<td>116.3 (40.5)</td>
<td>0.132</td>
</tr>
<tr>
<td>HDL-C, mean (SD)</td>
<td>50.8 (14.7)</td>
<td>50.9 (13.6)</td>
<td>0.920</td>
</tr>
<tr>
<td>Triglycerides, median (IQR)</td>
<td>113 (85)</td>
<td>105 (76)</td>
<td>0.220</td>
</tr>
<tr>
<td>Hemoglobin A1c, mean (SD)</td>
<td>8.9 (2.2)</td>
<td>8.3 (1.9)</td>
<td>0.006</td>
</tr>
<tr>
<td>PACIC, mean (SD)</td>
<td>1.5 (0.9)</td>
<td>1.6 (0.9)</td>
<td>0.883</td>
</tr>
</tbody>
</table>

LDL-C indicates low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; IRQ, interquartile range; and PACIC, Patient Assessment of Chronic Illness Care.
The sample was predominantly female (71%) and black (79%). A majority had at least a high school education; however, a majority had annual incomes <$20 000 and fewer than half had private health insurance. There were no significant differences in sociodemographic and baseline measures between the 2 groups except for higher total cholesterol and HbA1c levels in the NP/CHW intervention group compared with the EUC group (Table 1). We did not find statistically significant differential attrition between the two groups. Ninety-four percent (n=467) completed the 1-year assessment, with no differences between completers and noncompleters in baseline lipids, HbA1c, BP, age, education, race, or sex.

A total of 84% of patients randomly assigned to the intervention group completed an initial visit, and 70% had at least 4 in-person visits with the nurse. Patients in the intervention group had a mean of 7±3 in-person visits and 6±5 telephone visits with the NP/CHW team. A comprehensive cost-effectiveness analysis will be published separately.

At 12 months, patients in the intervention group had significantly greater overall improvement in total cholesterol, LDL-C, triglycerides, systolic and diastolic BP, HbA1c, and perceptions of the quality of their chronic illness care compared with patients receiving EUC (Table 2). The analyses using general linear mixed models controlled for age, sex, education, race, body mass index, insurance status, and an indicator of control status at baseline. The estimated between-group differences were clinically significant. At the 12-month follow-up, a significantly higher percentage of patients in the intervention group compared with the EUC group had values that reached guideline goals or showed clinically significant improvements in LDL-C (EUC=58%; I=75%, P<0.001), systolic BP (EUC=74%; I=82%, P=0.018), and HbA1c (EUC=47%; I=60%, P=0.016).

### Table 2. Changes in Primary Outcomes by Group

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Intervention Group (n=261)</th>
<th>Usual Care Group (n=264)</th>
<th>Estimated Between-Group Difference (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Change</td>
<td>Change</td>
<td>P Value</td>
</tr>
<tr>
<td>Systolic BP, mm Hg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>139.7±23.8</td>
<td>138.7±19.9</td>
<td>-6.2 (−10.2, −2.1)</td>
</tr>
<tr>
<td>1 y</td>
<td>130.8±20.7</td>
<td>135.9±20.5</td>
<td></td>
</tr>
<tr>
<td>Diastolic BP, mm Hg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>83.0±12.7</td>
<td>82.3±13.0</td>
<td>-0.7 (−1.3, −0.1)</td>
</tr>
<tr>
<td>1 y</td>
<td>77.4±12.5</td>
<td>79.7±12.6</td>
<td></td>
</tr>
<tr>
<td>Total cholesterol,† mg/dL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>199.7±46.0</td>
<td>191.3±45.0</td>
<td>-8.4 (−14.2, −2.6)</td>
</tr>
<tr>
<td>1 y</td>
<td>172.7±44.5</td>
<td>184.1±41.9</td>
<td></td>
</tr>
<tr>
<td>LDL,† mg/dL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>121.6±40.0</td>
<td>116.3±40.5</td>
<td>-5.3 (−10.2, −0.5)</td>
</tr>
<tr>
<td>1 y</td>
<td>100.1±39.2</td>
<td>110.6±36.8</td>
<td></td>
</tr>
<tr>
<td>Triglycerides,‡‡ mg/dL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>138.1±93.4</td>
<td>126.8±71.5</td>
<td>-16.6 (−29.6, −3.0)</td>
</tr>
<tr>
<td>1 y</td>
<td>121.3±81.6</td>
<td>123.1±72.2</td>
<td></td>
</tr>
<tr>
<td>HDL,† mg/dL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>50.8±14.7</td>
<td>50.9±13.6</td>
<td>0.1 (−0.9, 1.1)</td>
</tr>
<tr>
<td>1 y</td>
<td>49.4±13.5</td>
<td>49.9±12.9</td>
<td></td>
</tr>
<tr>
<td>Hemoglobin A1c, %</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>8.9±2.2</td>
<td>8.3±1.9</td>
<td>-0.5 (−0.9, −0.2)</td>
</tr>
<tr>
<td>1 y</td>
<td>8.3±2.2</td>
<td>8.2±1.9</td>
<td></td>
</tr>
<tr>
<td>PACIC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>1.6±0.9</td>
<td>1.6±1.0</td>
<td>0.0 (−0.2, 0.2)</td>
</tr>
<tr>
<td>1 y</td>
<td>2.9±0.9</td>
<td>1.8±1.0</td>
<td></td>
</tr>
</tbody>
</table>

*Intention-to-treat analysis using general linear mixed model with group, time, group by time effects, and covariates age, sex, education, body mass index, insurance, and an indicator of in-control for clinical outcome at baseline.

†To convert total cholesterol, LDL cholesterol, and HDL cholesterol to mmol/L, multiply by 0.0259; to convert triglycerides to mmol/L, multiply by 0.0113.

‡‡Computed using a trimmed mean of triglyceride values <1000. P value based on log-triglyceride values due to nonnormality.

CI indicates confidence interval; BP, blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; and PACIC, Patient Assessment of Chronic Illness Care.
Patients’ assessments of their chronic illness care improved significantly from baseline to 1 year in the intervention group (Table 3). This increase was significantly greater than the modest increase in the usual care group. These significantly different changes were present for the total score on the PACIC instrument as well as for the 5 subscales of Patient Activation, Delivery System Design/Decision Support, Goal Setting, Problem Solving/Contextual Counseling, and Follow-up Coordination.

Although there were greater changes in the recommended direction in the intervention group compared with usual care, there were no statistically significant differences in changes between groups in the level of physical activity, body mass index, total energy intake, saturated fat, or sodium intake from baseline to 1 year of follow-up.

### Discussion

This study demonstrated that vulnerable patients with uncontrolled CVD risk factors managed by an NP/CHW intervention team achieved significant improvement in their CVD risk profiles. The improvements in the primary outcomes in this study compare favorably with changes in other studies targeting improvement in clinical outcomes and quality of care in patients with CVD and/or diabetes. In a meta-analysis of 66 trials to improve the outcomes of diabetes care, the HbA1c level decreased by a mean of 0.42% (95% confidence interval [CI], 0.29–0.54) versus a mean of 0.50% (95% CI, 0.2–0.9) in this trial. In a recent review of 11 studies of nurse-led interventions used to improve control of high BP in people with diabetes, meta-analysis showed greater reductions in BP in favor of nurse-led interventions (systolic weighted mean difference −5.8 mm Hg; 95% CI, −9.6 to −2.0; diastolic weighted mean difference −4.2 mm Hg; 95% CI, −7.6 to −0.7). In a systematic review of 44 trials, systolic BP decreased by a mean of 4.5 mm Hg (95% CI, 1.8–6.6) versus a mean of 6.2 (95% CI, 2.1–10.2) in this trial. The changes in HbA1c, BP, total and LDL cholesterol, and triglycerides in this study are clinically meaningful. On a population level, they should lead to a meaningful decreases in macrovascular and microvascular disease in people with diabetes and decreases in events in people with CVD.

Patients in the intervention group rated the quality of care that they received for the management of their chronic conditions as increasing significantly more than patients who received usual care. Whether this translates into greater satisfaction with care is unclear; however, we know that satisfaction with care predicts better self-care and more favorable outcomes. The NP/CHW team enhanced patient self-care by encouraging self-monitoring, mutual goal-setting and decision-making, addressing barriers to improve adherence to medications and appointment keeping, and making proactive contact with patients to assess progress. These types of interventions are consistent with the strategies described by the Chronic Care Model to improve the performance of health care systems.

The results of this trial support the potential for nurse-led patient-centered medical homes (PCMH) to improve the quality of care in high-risk underserved populations. The concept of a PCMH is receiving increased attention as a means to improve care and potentially reduce costs. The PCMH has its origins in care for children with chronic heart disease. PCMH has its origins in care for children with chronic heart disease.
conditions. In March 2007, the American Academy of Pediatrics, American Academy of Family Practice, American College of Physicians, and American Osteopathic Association published a joint statement of principles calling for accessible, continuous, team-based care that focuses on the whole person, with the PCMH taking responsibility for care coordination. In 2009, the American College of Physicians endorsed the inclusion of NP-led practices to test different PCMH models within the Medical Home Demonstration Project. As the costs of health care for chronic diseases continue to increase, NPs are in pivotal positions to address the need for safe, effective, patient-centered, efficient, and equitable health care. This study also provides evidence that a nurse-led team that includes CHWs is an effective model of care. However, adoption and sustainability of this model of care will require financing mechanisms for CHWs. Funding, reimbursement, and payment policies for CHWs must be established to ensure that CHW models are adopted in mainstream health care.

The limitations of the COACH Trial include the fact that it was conducted in one federally qualified community health system and used highly trained NPs and CHWs, which may limit generalizability. Second, the recruitment and screening process resulted in the inclusion of a sample of predominately black women. However, this represents the majority of patients seen in these and other similar community health clinics, which increases confidence in the generalizability of findings to similar settings. Third, physicians had patients in both the intervention and EUC groups. This may have resulted in a change in the level of care provided to their patients in the EUC group as they received laboratory reports at baseline and tended to become more vigilant with the assessment, treatment, and follow-up for cardiovascular risk factor management. This may explain the improvements in clinical measures in the EUC group. Nevertheless, improvements in clinical outcomes and perceptions of the quality of care were significantly greater among patients in the intervention group compared with the EUC group. Finally, there was a higher attrition rate in the intervention group (13%) as compared with the EUC group (9%). However, the study was powered to account for a dropout rate of 25%. The slightly differential dropout rate in the intervention group may be due to the increased commitment to participate in the intervention group, including more visits to the clinic resulting in more costs to the participant.

Conclusions
In summary, an intervention delivered by a NP/CHW team, using individualized treatment regimens based on treat-to-target algorithms, can be an effective approach to improve risk factor status and perceptions of chronic illness care in high-risk patients. The translation of new knowledge and efficacious interventions into the care of populations, particularly those at highest risk of multiple chronic diseases, disability, and mortality, remains a national problem. This study developed a partnership with Baltimore Medical Systems, specifically to implement a program to reach this high-risk population. Moreover, the design and intervention were developed in collaboration with the Community Health Centers within this System, so that the program, if found efficacious, would be sustained for long-term effectiveness. Further analyses will evaluate the cost-effectiveness of NP/CHW model. Further study is needed to determine if this translates into improved morbidity and mortality from CVD.

Acknowledgments
We thank the patients who participated in the program and the administration and staff of Baltimore Medical Systems for their collaboration in the design and implementation of the program. We also thank Margaret Denny for assistance in the preparation of the manuscript.

Sources of Funding
This study was supported by the National Heart, Lung, and Blood Institute, National Institutes of Health grant R01HL082638.

Disclosures
None.

References


Community Outreach and Cardiovascular Health (COACH) Trial: A Randomized, Controlled Trial of Nurse Practitioner/Community Health Worker Cardiovascular Disease Risk Reduction in Urban Community Health Centers
Jerilyn K. Allen, Cheryl R. Dennison-Himmelfarb, Sarah L. Szanton, Lee Bone, Martha N. Hill, David M. Levine, Murray West, Amy Barlow, LaPricia Lewis-Boyer, Mary Donnelly-Strozzo, Carol Curtis and Katherine Anderson

Circ Cardiovasc Qual Outcomes. published online September 27, 2011;
Circulation: Cardiovascular Quality and Outcomes is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2011 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-7705. Online ISSN: 1941-7713

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circoutcomes.ahajournals.org/content/early/2011/09/27/CIRCOUTCOMES.111.961573

Data Supplement (unedited) at:
http://circoutcomes.ahajournals.org/content/suppl/2011/11/15/CIRCOUTCOMES.111.961573.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Cardiovascular Quality and Outcomes can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Cardiovascular Quality and Outcomes is online at:
http://circoutcomes.ahajournals.org//subscriptions/
SUPPLEMENTAL MATERIAL
**PRIMARY PREVENTION OF CVD**

**HYPERTENSION**

- **BASIC TREATMENT RECOMMENDATIONS**
  - Smoking Cessation/Reduction (counseling, meds, nicotine replacement)
  - Antiplatelet Therapy (Aspirin 81 mg qd) for at risk individuals
  - Exercise (30 minutes walking most days of the week; start 10-15 min 3x/week and increase as tolerated)
  - Weight Reduction if needed
  - Diet (low fat, low cholesterol, plant based, calorie restriction)
  - Stress Management

- **ASPIRIN TREATMENT RECOMMENDATIONS**
  - **WOMEN:** Consider if benefit of ischemic stroke prevention outweighs risk for GI bleed:
    - **AGE 55-59:** 10 year stroke risk ≥ 3%
    - **AGE 60-69:** 10 year stroke risk ≥ 8%
    - **AGE 70-79:** 10 year stroke risk ≥ 11%
  - **MEN:** Consider if benefit of MI prevention outweighs risk for GI bleed and hemorrhagic stroke:
    - **AGE 45-59:** 10 year CHD risk ≥ 4%
    - **AGE 60-69:** 10 year CHD risk ≥ 9%
    - **AGE 70-79:** 10 year CHD risk ≥ 12%

*The above applies to adults not taking NSAIDS and who do not have upper GI pain or GI ulcer history; based on 2009 USPSTF Recommendations.*

**DYSLIPIDEMIA**

- **ADDITIONAL CONDITION-SPECIFIC TREATMENT RECOMMENDATIONS**

- **HYPERTENSION**
  - **MEDICATIONS**
    - 1. Diuretic
    - 2. ACEI or ARB
    - 3. CCB
    - 4. BB
  - **MONITOR**
    - BP
    - Lipids
    - Weight
    - Lifestyle behavior
  - **GOALS**
    - BP < 139/89 mm Hg
    - or
    - BP < 129/79 mm Hg for Renal Disease

- **DYSLIPIDEMIA**
  - **MEDICATIONS**
    - 1. Statins
    - 2. Fibrate
    - 3. Nicotinic Acid
    - 4. Resins
    - 5. Ezetimibe
  - **MONITOR**
    - Lipids
    - BP
    - Weight
    - Lifestyle behavior
  - **GOALS**
    - LDL < 130 if moderate risk; Non HDL-C < 160
    - LDL < 160 if at lower risk; Non HDL-C < 190
    - TG < 150 for all
SECONDARY PREVENTION OF CVD
(or High Risk: Diabetes)

BASIC TREATMENT RECOMMENDATIONS
Smoking Cessation/Reduction (counseling, meds, nicotine patch)
Antiplatelet Therapy (ASA 81 mg or Clopidogrel 75 mg qd)
Exercise (30 minutes walking most days of the week; start 10-15 min 3x/week and increase as tolerated)
Weight Reduction if needed
Diet (ADA or low fat, low cholesterol, plant based, calorie restriction)
Stress Management

ADDITIONAL CONDITION-SPECIFIC TREATMENT RECOMMENDATIONS

DIABETES
• Diabetic teaching
• Medications
  1. Biguanides
  2. Thiazolidinedione
  3. Sulfonylureas
  4. Alpha glucosidase inhibitor
  5. Insulin

HYPTERTENSION
• Medications
  1. Diuretic
  2. ACEI or ARB
  3. CCB
  4. BB

DYSLIPIDEMIA
• Medications
  1. Statins
  2. Fibrates
  3. Nicotinic Acid
  4. Resins
  5. Ezetimibe

MONITOR
• FBS, HgbA1c
• Lipids
• BP
• Weight
• Lifestyle behavior

GOAL
FBS ≤ 100
HgbA1c ≤ 7.0%

MONITOR
• BP
• Lipids
• Weight
• Lifestyle behavior

GOAL
BP ≤ 129/79 mm Hg

MONITOR
• Lipids
• BP
• Weight
• Lifestyle behavior

GOAL
LDL < 70
Non HDL-C < 100
TG < 150

© Allen 2009
TREATMENT ALGORITHM FOR DIABETES

1. Diet/Exercise Counseling
2. Initiate glucose self-monitoring
3. Screen for target organ damage complications
4. Aspirin + Ace Inhibitors or ARB'S unless contraindicated

HgA1c ≤ 7%
- New Diagnosis
  - INITIATE ORAL AGENT
    - No Renal Disease: Metformin
    - Renal Disease: Other Oral Agent

HgA1c >7% to <10%
- On Single Oral Agent
  - ASSESS & REDUCE BARRIERS
    - Optimize adherence, dose, exercise, diet

HgA1c ≥ 10%
- or severely uncontrolled diabetes with catabolism**
  - INITIATE INSULIN
    - See Treatment Algorithm for Insulin Initiation & Adjustment

HgA1c >7% to <10%
- On Two Oral Agents
  - 2-4 week follow-up***
    - Adequate control? (Based on Glucose)

HgA1c >7% to <10%
- 2-4 week follow-up***
  - Adequate control? (Based on Glucose)

HgA1c ≤ 8.5%
- No

ADD SECOND ORAL AGENT *
- 2-4 week follow-up***
  - Adequate control? (Based on Glucose)

CONSIDER ADDING THIRD ORAL AGENT*
- Or Injectable GLP-1 Agonist

HgA1c ≤ 8.5%
- No

**INDICATIONS OF SEVERELY UNCONTROLLED DM
- Fasting glucose >250
- Random glucose consistently >300
- A1c > 10%
- Ketonuria
- Symptomatic: polyuria, polydipsia & weight loss.

RENAL DISEASE
- eGFR <60ml/min/1.73m²
- Cr >1.5 in men
- >1.3 in women
- Albuminuria >300mg/day (or 200mg albumin per gram of creatinine)

ACE-I OR ARB’S CONTRAINDICATIONS
- 1. Allergy
- 2. Pregnancy

ASPIRIN CONTRAINDICATIONS
- 1. Allergy
- 2. Ulcer
- 3. Pregnancy

*OPTIONS FOR ORAL AGENTS
- 1. Metformin
- 2. Sulfonylureas
- 3. Thiazolidinedione
- 4-5. DPP-4 Inhibitor
- 4-5. Glinide
- 6-7. Alpha-glucosidase inhibitor
- 6-7. Colesevelam

***12 weeks needed to determine effectiveness of Thiazolidinedione

© Allen 2008
TREATMENT ALGORITHM FOR HIGH BLOOD PRESSURE
WITHOUT DM, CAD AND/OR RENAL DISEASE

BP NORMAL
100-139 / 60-89 mm Hg

Is patient on recommended meds per
*COMORBIDITY - SPECIFIC MEDICAL CONSIDERATIONS?

Yes

No

Continue current dose

Consider med change

3 MONTH FOLLOW-UP
- BP
- Labs: creatinine/K+ if ACE-I or diuretic change
- Assess compliance

2-4 WEEK FOLLOW-UP
- BP
- Labs: creatinine/K+ if ACE-I or diuretic change
- Assess Compliance

BP LOW
< 100/60 mm Hg

Is patient on recommended meds per
COMORBIDITY - SPECIFIC MEDICAL CONSIDERATIONS?

Yes

No

Lower dose of current med

Consider med change

2 weeks - CHW visit or phone

4 weeks - NP visit

HTN STAGE 1
140-159 / 90-99 mm Hg

Is patient on recommended meds per
COMORBIDITY - SPECIFIC MEDICAL CONSIDERATIONS?

Yes

No

• Optimize dose of current med, or
• Add drug from another class

Consider med change

2-4 WEEK FOLLOW-UP OPTIONS:
- 2 weeks - CHW visit or phone
- 2-4 weeks - NP visit
- BP
- Labs: creatinine/K+ if ACE-I or diuretic change
- Assess Compliance

HTN STAGE 2
> 160/99 mm Hg

If initial visit: start 2 drug combination

If follow-up visit, is patient on recommended meds per
COMORBIDITY - SPECIFIC MEDICAL CONSIDERATIONS?

Yes

No

• Maximize dose of current med(s), or
• Add drug from another class

Consider med change

ANTIHYPERTENSIVE MED CONSIDERATIONS
- Thiazide-type diuretics for most
- ACE-I, ARB, BB, and / or CCB

*COMORBIDITY - SPECIFIC MEDICAL CONSIDERATIONS
- Prior MI or LV dysfunction - BB, ACE-I
- Prior Stroke - Diuretic, ACE-I
- African-American - Diuretic, CCB
- Heart Failure - Diuretic, CCB
  ➢Symptomatic – ACE-I, BB, ARB, aldosterone blockers, loop diuretics
  ➢Asymptomatic – ACE-I, BB

© Allen 2008
**TREATMENT ALGORITHM FOR HIGH BLOOD PRESSURE WITH DM, CAD AND/OR RENAL DISEASE**

**BP NORMAL**
100-129 / 60-79 mm Hg

Is patient on recommended meds per COMORBIDITY - SPECIFIC MEDICAL CONSIDERATIONS?
- Yes
  - Continue current dose
- No
  - Consider med change

**3 MONTH FOLLOW-UP**
- BP
- Labs: creatinine/K+ if ACE-I or diuretic change
- Assess compliance

**2-4 WEEK FOLLOW-UP**
- 2 weeks - CHW visit or phone
- 4 weeks - NP visit
- BP
- Labs: creatinine/K+ if ACE-I or diuretic change
- Assess Compliance

**ANTIHYPERTENSIVE MED CONSIDERATIONS**
- Thiazide-type diuretics for most
- ACE-I, ARB, BB, and/or CCB

**COMORBIDITY - SPECIFIC MEDICAL CONSIDERATIONS**
- Prior MI or LV dysfunction - BB, ACE-I
- Prior Stroke - Diuretic, ACE-I
- African-American - Diuretic, CCB
- Heart Failure - Diuretic, CCB
  > Symptomatic – ACE-I, BB, ARB, aldosterone blockers, loop diuretics
  > Asymptomatic – ACE-I, BB

**BP LOW**
< 100/60 mm Hg

Is patient on recommended meds per COMORBIDITY - SPECIFIC MEDICAL CONSIDERATIONS?
- Yes
  - Lower dose of current med
- No
  - Consider med change

**2-4 WEEK FOLLOW-UP OPTIONS:**
- 2 weeks - CHW visit or phone
- 2-4 weeks - NP visit
  - BP
  - Labs: creatinine/K+ if ACE-I or diuretic change
  - Assess Compliance

**BP ELEVATED**
130-159 / 80-99 mm Hg

Is patient on recommended meds per COMORBIDITY - SPECIFIC MEDICAL CONSIDERATIONS?
- Yes
  - Optimize dose of current med, or
  - Add drug from another class
- No
  - Consider med change

**RENAL DISEASE**
- eGFR <60 ml/min/1.73m²
- Cr >1.5 in men
  >1.3 in women
- Albuminuria >300 mg/day
  (or 200 mg albumin per gram of creatinine)

**BP NORMAL**
100-129 / 60-79 mm Hg

Is patient on recommended meds per COMORBIDITY - SPECIFIC MEDICAL CONSIDERATIONS?
- Yes
  - Continue current dose
- No
  - Consider med change

**2-4 WEEK FOLLOW-UP OPTIONS:**
- 2 weeks - CHW visit or phone
- 2-4 weeks - NP visit
  - BP
  - Labs: creatinine/K+ if ACE-I or diuretic change
  - Assess Compliance

**HTN STAGE 2**
>160/99 mm Hg

If initial visit: start 2 drug combination

If follow-up visit, is patient on recommended meds per COMORBIDITY - SPECIFIC MEDICAL CONSIDERATIONS?
- Yes
  - Consider med change
- No
  - Maximize dose of current med(s), or
  - Add drug from another class

Consider med change

© Allen 2008
TREATMENT ALGORITHM FOR INSULIN INITIATION AND ADJUSTMENT

HgA1c > 7%
- On combination oral therapy

Assess & Reduce Barriers:
- Intensive Pt Education
- Use of delivery device
- Self monitoring of glucose
- Meds, diet & exercise optimized?
- 2-4 wk follow up; Adequate control?

Assess Risk/Benefit:
- Consider hypoglycemia risk, life expectancy & age.
- Upward adjustment of HgA1C goal needed?

Consider Barriers:
- Skills/abilities, financial, psychosocial issues.
- Appropriate patient for management with insulin?
- Consult Specialist
- ↓ Dose Sulfonylurea
- Continue other oral meds
- Decrease insulin dose & adjust follow up
- Stop insulin secretagogues (sulfonylurea or glinide)
- Continue other oral meds
- Consult specialist
- Check 2 hrs post-prandial glucose → Out of range?
- Adjust/add pre-prandial rapid acting insulin** and/or consult specialist

Initiate Insulin*
- On Sulfonylurea?
- No
- Continue oral medications
- Follow Up Options: weekly visits x 1 mo → clinic or home/tel visit
- Titrate doses by SMBG until FBG 70-130, usually 2units q 3days
- Hypoglycemia or FBS < 70?
- No
- HgA1c ≤ 7% after 2-3 mos?
- No
- If FBG in range, check pre-prandial glucose & add second injection**
- On Sulfonylurea or Glinide?
- No
- Continue other oral meds
- Consult specialist
- HgA1c ≤ 7% after 2-3 mos?
- No
- Re-check pre-prandial glucose → Out of range?
- Yes
- Adjust/add pre-prandial rapid acting insulin**
- HgA1c ≤ 7% after 2-3 mos?
- No
- SMBG = Self Monitoring of Blood Glucose
- FBG = Fasting Blood Glucose

*Options for Starting Regimens
- 10u or 0.2units/kg
- 1. Once daily long-acting insulin
- 2. Bedtime intermediate-acting (NPH)

**Options for Second Injection
- If glucose out of range:
  - Pre-lunch → add rapid-acting at breakfast
  - Pre-dinner → add breakfast NPH or rapid-acting at lunch
  - Pre-bed → add rapid-acting at dinner

HgA1c q 3 mos

© Allen 2008
**TREATMENT ALGORITHM FOR ANTIHYPERLIPIDEMIC DRUG THERAPY**

**LDL AT GOAL?**

- **Yes**
  - TLC
  - LDL < 50?
    - Yes
      - TG > 200?
        - No
          - TG 200-499
            - On fibrate or niacin?
              - Yes
                - Maximize dose
              - No
                - Initiate fibrate or niacin
                  - Recheck in 4-6 weeks
            - No
              - TG < 200
                - Increase statin dose or Change to more potent statin*
                  - Increase dose
                    - Recheck in 4-6 weeks
                  - TG < 200
                    - Increase statin dose
                      - Recheck in 4-6 weeks
              - TG 200-499
                - Increase statin dose or Change to more potent statin*
                  - Increase dose
                    - Recheck in 4-6 weeks
                  - On statin?
                    - No
                      - On maximum dose?
                        - Yes
                          - Initiate fibrate or niacin
                        - No
                          - Initiate statin
                            - Yes
                              - Recheck in 4-6 weeks
                            - No
                              - On statin?
                                - Yes
                                  - Recheck in 4-6 weeks
                                - No
                                  - Maximize dose
      - No
        - TG > 500
          - On fibrate or niacin?
            - Yes
              - TG < 200
                - Increase statin dose or Change to more potent statin*
                  - Increase dose
                    - Recheck in 4-6 weeks
                - TG 200-499
                  - Increase statin dose
                    - Recheck in 4-6 weeks
            - No
              - Recheck in 4-6 weeks
              - LDL AT GOAL?
                - Yes
                  - TLC
                  - LDL < 50?
                    - Yes
                      - TG > 200?
                        - No
                          - TG 200-499
                            - On fibrate or niacin?
                              - Yes
                                - Maximize dose
                              - No
                                - Initiate fibrate or niacin
                                  - Recheck in 4-6 weeks
                            - No
                              - TG < 200
                                - Increase statin dose or Change to more potent statin*
                                  - Increase dose
                                    - Recheck in 4-6 weeks
                                - TG < 200
                                  - Increase statin dose
                                    - Recheck in 4-6 weeks
                                - TG 200-499
                                  - Increase statin dose
                                    - Recheck in 4-6 weeks
                          - No
                            - TG > 500
                              - On fibrate or niacin?
                                - Yes
                                  - TG < 200
                                    - Increase statin dose or Change to more potent statin*
                                      - Increase dose
                                        - Recheck in 4-6 weeks
                                    - TG 200-499
                                      - Increase statin dose
                                        - Recheck in 4-6 weeks
                                - No
                                  - Recheck in 4-6 weeks
              - TLC
                - LDL < 50?
                  - Yes
                    - TG > 200?
                      - No
                        - TG 200-499
                          - On fibrate or niacin?
                            - Yes
                              - Maximize dose
                            - No
                              - Initiate fibrate or niacin
                                - Recheck in 4-6 weeks
                          - No
                            - TG < 200
                              - Increase statin dose or Change to more potent statin*
                                - Increase dose
                                  - Recheck in 4-6 weeks
                              - TG < 200
                                - Increase statin dose
                                  - Recheck in 4-6 weeks
                              - TG 200-499
                                - Increase statin dose
                                  - Recheck in 4-6 weeks
                          - No
                            - TG > 500
                              - On fibrate or niacin?
                                - Yes
                                  - TG < 200
                                    - Increase statin dose or Change to more potent statin*
                                      - Increase dose
                                        - Recheck in 4-6 weeks
                                    - TG 200-499
                                      - Increase statin dose
                                        - Recheck in 4-6 weeks
                                - No
                                  - Recheck in 4-6 weeks
              - No
                - LDL AT GOAL?
                  - Yes
                    - TLC
                    - LDL < 50?
                      - Yes
                        - TG > 200?
                          - No
                            - TG 200-499
                              - On fibrate or niacin?
                                - Yes
                                  - Maximize dose
                                - No
                                  - Initiate fibrate or niacin
                                    - Recheck in 4-6 weeks
                              - No
                                - TG < 200
                                  - Increase statin dose or Change to more potent statin*
                                    - Increase dose
                                      - Recheck in 4-6 weeks
                                  - TG < 200
                                    - Increase statin dose
                                      - Recheck in 4-6 weeks
                                  - TG 200-499
                                    - Increase statin dose
                                      - Recheck in 4-6 weeks
                          - No
                            - TG > 500
                              - On fibrate or niacin?
                                - Yes
                                  - TG < 200
                                    - Increase statin dose or Change to more potent statin*
                                      - Increase dose
                                        - Recheck in 4-6 weeks
                                    - TG 200-499
                                      - Increase statin dose
                                        - Recheck in 4-6 weeks
                                - No
                                  - Recheck in 4-6 weeks
                    - TLC
                      - LDL < 50?
                        - Yes
                          - TG > 200?
                            - No
                              - TG 200-499
                                - On fibrate or niacin?
                                  - Yes
                                    - Maximize dose
                                  - No
                                    - Initiate fibrate or niacin
                                      - Recheck in 4-6 weeks
                              - No
                                - TG < 200
                                  - Increase statin dose or Change to more potent statin*
                                    - Increase dose
                                      - Recheck in 4-6 weeks
                                  - TG < 200
                                    - Increase statin dose
                                      - Recheck in 4-6 weeks
                                  - TG 200-499
                                    - Increase statin dose
                                      - Recheck in 4-6 weeks
                          - No
                            - TG > 500
                              - On fibrate or niacin?
                                - Yes
                                  - TG < 200
                                    - Increase statin dose or Change to more potent statin*
                                      - Increase dose
                                        - Recheck in 4-6 weeks
                                    - TG 200-499
                                      - Increase statin dose
                                        - Recheck in 4-6 weeks
                                - No
                                  - Recheck in 4-6 weeks
Snore

**FOR DIABETICS:**
- If TG > 150, optimize glycemic control concurrently with lipid-lowering drug therapy.
- Fibrates preferred over niacin.

**LDL Goals:**
- **High Risk:** CHD or CHD risk equivalent <70
- **Mod. High Risk:** 2+ risk factors (10yr risk 10-20%) <130 (<100)
- **Moderate Risk:** 2+ risk factors (10yr risk <10%) <130
- **Lower Risk:** 0-1 risk factor <160

***Non-HDL-C** is used for TG > 200 or if sample drawn non-fasting.

**TLC = Therapeutic Lifestyle Change**

**Maximize statin use** prior to use of ezetimibe or other second line treatment

© Allen 2008
Figure Legend
Figure 1. CONSORT diagram of COACH Trial

Assessed for Eligibility (n=3899)
  Excluded (n=3374)
    Failed to meet inclusion criteria (n=2053)
    Unable to contact (n=622)
    Declined to participate (n=699)

Randomized (n=525)

Assigned to Intervention (n=261)
  Attrition (n=34)
    Unable to contact (n=24)
    Died (n=3)
    Moved (n=5)
    Withdrew (n=2)

  Analyzed (n=261)
  Excluded from analysis (n=0)

Assigned to Usual Care (n=264)
  Attrition (n=24)
    Unable to contact (n=19)
    Died (n=3)
    Moved (n=5)
    Withdrew (n=2)

  Analyzed (n=264)
  Excluded from analysis (n=0)
Dear Dr. Allen,

I hereby give you permission to be named in the acknowledgement section of your journal article “COACH Trial: A Randomized Controlled Trial of Nurse Practitioner/Community Health Worker Cardiovascular Disease Risk Reduction in Urban Community Health Centers”, manuscript ID# CiRCCVOQ/2011/961573.

Please let me know if you need anything further.

Sincerely,

Margaret Denny

August 11, 2011

Jerilyn Allen, RN, ScD, FAAN
525 N. Wolfe Street
Room 534
Baltimore, MD 21205